DJIA 17,022.20 47.89 0.28%
NASDAQ 4,533.69 -15.53 -0.34%
S&P 500 1,979.66 -2.64 -0.13%
market minute promo

34.71 -0.03 (-0.09%)

Quote as of


company name or ticker

Recent Quotes

XLRN $34.71 -0.09%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $34.71
Previous Close $34.74
Daily Range $34.71 - $34.71
52-Week Range $16.78 - $57.89
Market Cap $1.1B
P/E Ratio -6.75
Dividend (Yield) $0.00 (0.0%)
Volume 367
Average Daily Volume 238,496
Current FY EPS -$1.35

Sector

Industry

CONTROLADORA VUELA SPON ADR REPR 10 CPOS (XLRN) Description

CONTROLADORA VUELA SPON ADR REPR 10 CPOS Website: http://www.acceleronpharma.com/

News & Commentary

A Quick Look at Celgene Corporation's Drug Development Pipeline

Celgene's drug development pipeline is currently firing on all cylinders; but can it stay that way for long? Find out as we take a closer look at the experimental drugs which matter most to Celgene.

Sector Update: Health-care Stocks Higher Pre-Bell

Sector Update: Health Care

Acceleron Initiates Phase 1 Clinical Trial With Innovative Muscle Drug ACE-083

Acceleron Hit Over Competitive Concerns, But Investors Overlook Rest of Pipeline

Will Acceleron (XLRN) Continue to Surge Higher? - Tale of the Tape

Acceleron Pharma (XLRN) Jumps: Stock Rises 12.8% - Tale of the Tape

Acceleron Offers Update on Externally-Sponsored Clinical Trial of Dalantercept Monotherapy in Ovaria

Acceleron Offers Update on Externally-Sponsored Clinical Trial of Dalantercept Monotherapy in Ovarian Cancer

Acceleron Pharma's (XLRN) CEO John Knopf on Q2 2014 Results - Earnings Call Transcript

Celgene's Pomalyst Data at European Hematology Association Shows Promise - Analyst Blog

See More XLRN News...